Camlin Fine Sciences Q1 FY27 Results: Revenue Up 23%

Key takeaway from the June 2026 quarter

Camlin Fine Sciences Ltd reported strong top-line growth in Q1 FY27, but the quarter ended with a deeper consolidated loss as margins came under pressure. The company’s consolidated revenue for the quarter ended June 30, 2026 was reported at around ₹519 crore, up sharply year on year. However, the consolidated net loss widened to roughly ₹33.62 crore (also reported as about ₹35 crore in some summaries) versus a loss of about ₹10.68-11 crore in Q1 FY26. The results were announced on August 11, 2026. On the same day, the stock was cited at a CMP of ₹126.

When the results were announced and what period they cover

The company’s Q1 FY27 results were announced on August 11, 2026. The financials discussed are on a consolidated basis for the quarter ended June 30, 2026. The reporting also references the company’s Q1 FY27 earnings call dated August 11, 2026. The disclosures combine financial results and commentary on operating conditions, including the impact of cost inflation and exceptional items.

Headline numbers: revenue up, loss wider

Reported revenue from operations rose to about ₹519 crore in Q1 FY27 from ₹423 crore in Q1 FY26, a year-on-year increase of 22.74% as cited in the results summary. Another disclosure described revenue at ₹519.88 crore for the quarter. Separately, the earnings call summary described revenue of ₹519.9 crore (INR 5,199 million), also indicating a year-on-year growth rate of 28% in that source. Profitability remained weak, with the consolidated net loss stated as ₹33.62 crore (₹336.22 million). In other result summaries, the net loss was rounded to about ₹35 crore.

Margin pressure: costs and financing weighed on profitability

Management commentary tied the weaker profitability to elevated raw material inflation, freight and logistics costs, and financing expenses. A summary of the earnings call stated that gross margin fell to 4% from 45% in Q4 FY26, highlighting the extent of near-term pressure. The same narrative noted EBITDA margin dropping to about 3.4% to 4%. One disclosure cited EBITDA at about ₹9 crore, while another cited adjusted or operational EBITDA of ₹17.6 crore (₹176 million), with an EBITDA margin of 3.40% versus 4.98% a year earlier. These figures, taken together, point to a quarter where volumes and revenue improved, but cost headwinds and below-normal conditions constrained earnings.

Segment view: new reporting split across three businesses

The company introduced segmental reporting, dividing the business into specialty ingredients, aroma (vanillin), and performance chemicals. Specialty ingredient revenue was stated to have exceeded ₹400 crore (INR 4,000 million). Within that, blends contributed over ₹300 crore (INR 3,000 million), while straights were reported at ₹92.7 crore (INR 927 million). In performance chemicals, EBITDA was stated at 1.5%, with commentary pointing to a diphenol plant shutdown and high raw material costs. The segment split is relevant because it helps investors track where growth is coming from and which lines are most exposed to cost swings.

Vanillin ramp-up: Italy operations and customer qualification

Camlin Fine Sciences also provided an operational update on vanillin. The company said it successfully ramped up Italian vanillin production, selling 350 metric tons in Q1 and achieving qualification with 95% of its customers. Another disclosure stated the aroma segment sold 560 tons of vanillin in the quarter, including 350 tons of methyl vanillin and 200 tons from channel stocks. These details matter because scaling and customer qualification can influence mix, capacity utilisation, and the stability of order flows in subsequent quarters. The data also signals continued focus on aroma products even as broader cost pressures impact margins.

Exceptional item: insurance settlement shortfall linked to Brazil fire

An exceptional item was also flagged as a drag on quarterly profitability. The earnings summary cited an exceptional item of ₹11.1 crore (₹111 million), recorded as a shortfall in the settlement of an insurance claim related to a fire at the Brazil unit. The same summary noted that PAT from continuing operations was negative at about ₹31.8 crore (₹318 million). The consolidated net loss after tax and exceptional items was reported at ₹33.62 crore (₹336.22 million). This suggests that, beyond operating pressures, one-off items also affected the reported bottom line.

Market snapshot: stock price cited at ₹126 on results day

Camlin Fine Sciences’ share price was cited at ₹126 on August 11, 2026, the day the results were declared. The disclosures provided do not include an intraday move or a specific percentage change for that day. Still, the CMP reference gives readers a point-in-time context for how the market was valuing the company as it reported record revenue alongside weak profitability.

Summary table of reported metrics

Guidance and what management expects next

Management expectations presented in the earnings materials included a near-term recovery in EBITDA margins to the 10-12% range and 12-14% in fiscal 2028 as utilisation improves. Another outlook statement projected full-year revenue of ₹2,200-2,300 crore with EBITDA margins of 10-11%. The same outlook described a sequential improvement path, with Q2 expected to be better than Q1, Q3 returning to double-digit EBITDA margins, and second-half margins potentially reaching 13-15%. These are management expectations, not reported outcomes, and they assume improvement from the cost and disruption factors described for Q1.

Why this quarter matters for investors

The quarter highlights a clear split between growth and profitability. On one hand, revenue reached around ₹519 crore and was described as the highest-ever quarterly revenue in the earnings summary. On the other hand, gross profit and net profit metrics were weak, with the reported net loss widening year on year. The segment disclosure and operational details on vanillin suggest the company is building scale in key product lines, but the near-term financial story is still dominated by cost inflation, logistics, and exceptional items. For investors, upcoming quarters will likely be judged on whether margins recover as guided and whether exceptional impacts subside.

Conclusion

Camlin Fine Sciences delivered strong revenue growth in Q1 FY27, but the quarter ended with a wider consolidated loss of about ₹34-35 crore as costs and exceptional items weighed on results. The company announced the results on August 11, 2026 for the quarter ended June 30, 2026, with the stock cited at ₹126 that day. Management has outlined a margin recovery path and a full-year revenue outlook, with improvement expected sequentially after a weak start to FY27. Investors will watch subsequent quarterly results and updates on utilisation, raw material trends, and any further exceptional items.